Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06439535 versus bevacizumab-EU with paclitaxel/carboplatin in first-line advanced non-squamous NSCLC
NL-OMON45020Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-bvzr, bevacizumab, paclitaxel and carboplatin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Confirmed objective response rate. Started Oct 2015; status: active, not recruiting.
02
Drugs
bevacizumab-bvzrbevacizumabpaclitaxelcarboplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on NL-OMON45020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45020.